Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2559)	10/5/2009 12:29:10 PM
From: Jibacoa	Respond to of 3722

AVII is up 25.64% with volume of > 17,154,200 about 5x its ADV The stock is been helped by an article in Barron's and the announcenment that it received a contract of approximately $11.5M from DTRA's TMTI to support development of the IND for its AVI-7012, to treat Junin virus infection. Already the US DoD has contracted with AVII for work potentially worth up to $45M for the development of its RNA-based drug candidates to treat Ebola, Marburg and Junin virus infections (AVI-6002, AVI-6003 and AVI-7012.) The stock opened with a small UG and traded for a while above $2, but so far, still below its Sep14 H of $2.22 It needs to close above that resistance before it can re-test its July 30 H at $2.73 <g> bigcharts.marketwatch.com AVII has reported lower revenues on the last 2Qs and the loss on the 2ndQ was substantially higher ($0.23 vs. $0.02) The ACTAY is $3.75. It seems that with some further good news the stock could get there, but I think that I will wait for it to close above its nearest resistance.<g> bigcharts.marketwatch.com Bernard